000270650 001__ 270650
000270650 005__ 20240728004316.0
000270650 0247_ $$2doi$$a10.1001/jamanetworkopen.2024.19282
000270650 0247_ $$2pmid$$apmid:38967926
000270650 0247_ $$2pmc$$apmc:PMC11227088
000270650 0247_ $$2altmetric$$aaltmetric:165133758
000270650 037__ $$aDZNE-2024-00822
000270650 041__ $$aEnglish
000270650 082__ $$a610
000270650 1001_ $$0P:(DE-2719)2810763$$aMichalowsky, Bernhard$$b0$$eFirst author$$udzne
000270650 245__ $$aClinical Outcomes and Cost-Effectiveness of Collaborative Dementia Care: A Secondary Analysis of a Cluster Randomized Clinical Trial.
000270650 260__ $$aChicago, Ill.$$bAmerican Medical Association$$c2024
000270650 3367_ $$2DRIVER$$aarticle
000270650 3367_ $$2DataCite$$aOutput Types/Journal article
000270650 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1721644088_12033
000270650 3367_ $$2BibTeX$$aARTICLE
000270650 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000270650 3367_ $$00$$2EndNote$$aJournal Article
000270650 520__ $$aLong-term evidence for the effectiveness and cost-effectiveness of collaborative dementia care management (CDCM) is lacking.To evaluate whether 6 months of CDCM is associated with improved patient clinical outcomes and caregiver burden and is cost-effective compared with usual care over 36 months.This was a prespecified secondary analysis of a general practitioner (GP)-based, cluster randomized, 2-arm clinical trial conducted in Germany from January 1, 2012, to December 31, 2014, with follow-up until March 31, 2018. Participants were aged 70 years or older, lived at home, and screened positive for dementia. Data were analyzed from March 2011 to March 2018.The intervention group received CDCM, comprising a comprehensive needs assessment and individualized interventions by nurses specifically qualified for dementia care collaborating with GPs and health care stakeholders over 6 months. The control group received usual care.Main outcomes were neuropsychiatric symptoms (Neuropsychiatric Inventory [NPI]), caregiver burden (Berlin Inventory of Caregivers' Burden in Dementia [BIZA-D]), health-related quality of life (HRQOL, measured by the Quality of Life in Alzheimer Disease scale and 12-Item Short-Form Health Survey [SF-12]), antidementia drug treatment, potentially inappropriate medication, and cost-effectiveness (incremental cost per quality-adjusted life year [QALY]) over 36 months. Outcomes between groups were compared using multivariate regression models adjusted for baseline scores.A total of 308 patients, of whom 221 (71.8%) received CDCM (mean [SD] age, 80.1 [5.3] years; 142 [64.3%] women) and 87 (28.2%) received usual care (mean [SD] age, 79.2 [4.5] years; 50 [57.5%] women), were included in the clinical effectiveness analyses, and 428 (303 [70.8%] CDCM, 125 [29.2%] usual care) were included in the cost-effectiveness analysis (which included 120 patients who had died). Participants receiving CDCM showed significantly fewer behavioral and psychological symptoms (adjusted mean difference [AMD] in NPI score, -10.26 [95% CI, -16.95 to -3.58]; P = .003; Cohen d, -0.78 [95% CI, -1.09 to -0.46]), better mental health (AMD in SF-12 Mental Component Summary score, 2.26 [95% CI, 0.31-4.21]; P = .02; Cohen d, 0.26 [95% CI, -0.11 to 0.51]), and lower caregiver burden (AMD in BIZA-D score, -0.59 [95% CI, -0.81 to -0.37]; P < .001; Cohen d, -0.71 [95% CI, -1.03 to -0.40]). There was no difference between the CDCM group and usual care group in use of antidementia drugs (adjusted odds ratio, 1.91 [95% CI, 0.96-3.77]; P = .07; Cramér V, 0.12) after 36 months. There was no association with overall HRQOL, physical health, or use of potentially inappropriate medication. The CDCM group gained QALYs (0.137 [95% CI, 0.000 to 0.274]; P = .049; Cohen d, 0.20 [95% CI, -0.09 to 0.40]) but had no significant increase in costs (437€ [-5438€ to 6313€] [US $476 (95% CI, -$5927 to $6881)]; P = .87; Cohen d, 0.07 [95% CI, -0.14 to 0.28]), resulting in a cost-effectiveness ratio of 3186€ (US $3472) per QALY. Cost-effectiveness was significantly better for patients living alone (CDCM dominated, with lower costs and more QALYs gained) than for those living with a caregiver (47 538€ [US $51 816] per QALY).In this secondary analysis of a cluster randomized clinical trial, CDCM was associated with improved patient, caregiver, and health system-relevant outcomes over 36 months beyond the intervention period. Therefore, it should become a health policy priority to initiate translation of CDCM into routine care.ClinicalTrials.gov Identifier: NCT01401582.
000270650 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000270650 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000270650 650_2 $$2MeSH$$aHumans
000270650 650_2 $$2MeSH$$aCost-Benefit Analysis
000270650 650_2 $$2MeSH$$aFemale
000270650 650_2 $$2MeSH$$aMale
000270650 650_2 $$2MeSH$$aDementia: therapy
000270650 650_2 $$2MeSH$$aDementia: economics
000270650 650_2 $$2MeSH$$aAged
000270650 650_2 $$2MeSH$$aAged, 80 and over
000270650 650_2 $$2MeSH$$aQuality of Life
000270650 650_2 $$2MeSH$$aCaregivers: psychology
000270650 650_2 $$2MeSH$$aGermany
000270650 650_2 $$2MeSH$$aCaregiver Burden: psychology
000270650 650_2 $$2MeSH$$aQuality-Adjusted Life Years
000270650 7001_ $$0P:(DE-2719)9001870$$aBlotenberg, Iris$$b1$$udzne
000270650 7001_ $$0P:(DE-2719)9001238$$aPlaten, Moritz$$b2$$udzne
000270650 7001_ $$0P:(DE-2719)2000026$$aTeipel, Stefan$$b3$$udzne
000270650 7001_ $$0P:(DE-2719)2810394$$aKilimann, Ingo$$b4$$udzne
000270650 7001_ $$aPortacolone, Elena$$b5
000270650 7001_ $$aBohlken, Jens$$b6
000270650 7001_ $$0P:(DE-2719)9001134$$aRädke, Anika$$b7$$udzne
000270650 7001_ $$0P:(DE-2719)9002138$$aBuchholz, Maresa$$b8$$udzne
000270650 7001_ $$0P:(DE-2719)9001251$$aScharf, Annelie$$b9$$udzne
000270650 7001_ $$0P:(DE-2719)9001235$$aMuehlichen, Franka$$b10$$udzne
000270650 7001_ $$aXie, Feng$$b11
000270650 7001_ $$0P:(DE-2719)2290613$$aThyrian, Jochen René$$b12$$udzne
000270650 7001_ $$0P:(DE-2719)2000040$$aHoffmann, Wolfgang$$b13$$eLast author$$udzne
000270650 773__ $$0PERI:(DE-600)2931249-8$$a10.1001/jamanetworkopen.2024.19282$$gVol. 7, no. 7, p. e2419282 -$$n7$$pe2419282$$tJAMA network open$$v7$$x2574-3805$$y2024
000270650 8564_ $$uhttps://pub.dzne.de/record/270650/files/DZNE-2024-00822%20SUP1.pdf
000270650 8564_ $$uhttps://pub.dzne.de/record/270650/files/DZNE-2024-00822%20SUP2.pdf
000270650 8564_ $$uhttps://pub.dzne.de/record/270650/files/DZNE-2024-00822%20SUP3.pdf
000270650 8564_ $$uhttps://pub.dzne.de/record/270650/files/DZNE-2024-00822.pdf$$yOpenAccess
000270650 8564_ $$uhttps://pub.dzne.de/record/270650/files/DZNE-2024-00822%20SUP1.pdf?subformat=pdfa$$xpdfa
000270650 8564_ $$uhttps://pub.dzne.de/record/270650/files/DZNE-2024-00822%20SUP2.pdf?subformat=pdfa$$xpdfa
000270650 8564_ $$uhttps://pub.dzne.de/record/270650/files/DZNE-2024-00822%20SUP3.pdf?subformat=pdfa$$xpdfa
000270650 8564_ $$uhttps://pub.dzne.de/record/270650/files/DZNE-2024-00822.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000270650 909CO $$ooai:pub.dzne.de:270650$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000270650 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810763$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000270650 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001870$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000270650 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001238$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000270650 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000270650 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810394$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000270650 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001134$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000270650 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002138$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000270650 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001251$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000270650 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001235$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000270650 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2290613$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000270650 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000040$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000270650 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000270650 9141_ $$y2024
000270650 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000270650 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-27
000270650 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000270650 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJAMA NETW OPEN : 2022$$d2023-10-27
000270650 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJAMA NETW OPEN : 2022$$d2023-10-27
000270650 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-10-18T13:36:16Z
000270650 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-10-18T13:36:16Z
000270650 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-27
000270650 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-27
000270650 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000270650 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000270650 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-10-18T13:36:16Z
000270650 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-27
000270650 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000270650 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-27
000270650 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000270650 9201_ $$0I:(DE-2719)1510600$$kAG Hoffmann$$lTranslational Health Care Research$$x0
000270650 9201_ $$0I:(DE-2719)5000067$$kAG Michalowsky ; AG Michalowsky$$lPatient-Reported Outcomes and Health Economics Research$$x1
000270650 9201_ $$0I:(DE-2719)1510800$$kAG Thyrian$$lInterventional Health Care Research (IHCR)$$x2
000270650 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x3
000270650 980__ $$ajournal
000270650 980__ $$aVDB
000270650 980__ $$aUNRESTRICTED
000270650 980__ $$aI:(DE-2719)1510600
000270650 980__ $$aI:(DE-2719)5000067
000270650 980__ $$aI:(DE-2719)1510800
000270650 980__ $$aI:(DE-2719)1510100
000270650 9801_ $$aFullTexts